EMA Investigates Risk of Suicidal Thoughts and Self-Harm from GLP-1 Receptor Agonists
The European Medicines Agency (EMA) announced on Tuesday that it is currently conducting a comprehensive review of data concerning the potential risk of suicidal thoughts and self-harm associated with the…